These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 29099660)

  • 1. Ten-Year Retention Rate of Infliximab in Patients with Behçet's Disease-Related Uveitis.
    Fabiani C; Sota J; Vitale A; Emmi G; Vannozzi L; Bacherini D; Lopalco G; Guerriero S; Venerito V; Orlando I; Franceschini R; Fusco F; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
    Ocul Immunol Inflamm; 2019; 27(1):34-39. PubMed ID: 29099660
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up study.
    Fabiani C; Sota J; Vitale A; Rigante D; Emmi G; Vannozzi L; Bacherini D; Lopalco G; Guerriero S; Gentileschi S; Capozzoli M; Franceschini R; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
    Br J Ophthalmol; 2018 May; 102(5):637-641. PubMed ID: 28844047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Study of Infliximab Versus Adalimumab in Refractory Uveitis due to Behçet's Disease: National Multicenter Study of 177 Cases.
    Atienza-Mateo B; Martín-Varillas JL; Calvo-Río V; Demetrio-Pablo R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adan A; Hernández MV; Hernández-Garfella M; Valls-Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero-Coma M; Díaz-Llopis M; Gallego R; García-Serrano JL; Ortego-Centeno N; Herreras JM; Fonollosa A; Garcia-Aparicio ÁM; Maíz-Alonso O; Blanco A; Torre-Salaberri I; Fernandez-Espartero C; Jovaní V; Peiteado D; Pato E; Cruz J; Férnandez-Cid C; Aurrecoechea E; García-Arias M; Castañeda S; Caracuel-Ruiz MA; Montilla-Morales CA; Atanes-Sandoval A; Francisco F; Insua S; González-Suárez S; Sanchez-Andrade A; Gamero F; Linares Ferrando LF; Romero-Bueno F; García-González AJ; González RA; Muro EM; Carrasco-Cubero C; Olive A; Prior Á; Vázquez J; Ruiz-Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernandez S; Fernández-Carballido C; Rubio-Romero E; Pages FA; Toyos-Sáenz de Miera FJ; Martinez MG; Díaz-Valle D; López Longo FJ; Nolla JM; Álvarez ER; Martínez MR; González-López JJ; Rodríguez-Cundin P; Hernández JL; González-Gay MA; Blanco R
    Arthritis Rheumatol; 2019 Dec; 71(12):2081-2089. PubMed ID: 31237427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 10-year follow-up of infliximab monotherapy for refractory uveitis in Behçet's syndrome.
    Horiguchi N; Kamoi K; Horie S; Iwasaki Y; Kurozumi-Karube H; Takase H; Ohno-Matsui K
    Sci Rep; 2020 Dec; 10(1):22227. PubMed ID: 33335139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term retention rates of adalimumab and infliximab in non-infectious intermediate, posterior, and panuveitis.
    Fabiani C; Vitale A; Emmi G; Bitossi A; Lopalco G; Sota J; Guerriero S; Orlando I; Capozzoli M; Fusco F; Rana F; Iannone F; Frediani B; Galeazzi M; Vannozzi L; Tosi GM; Cantarini L
    Clin Rheumatol; 2019 Jan; 38(1):63-70. PubMed ID: 29611087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term outcomes of infliximab in patients with Behçet's disease-associated uveitis.
    Yamana S; Hasegawa E; Takeda A; Yawata N; Sonoda KH
    Int Ophthalmol; 2023 Mar; 43(3):937-944. PubMed ID: 36057758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin (IL)-1 inhibition with anakinra and canakinumab in Behçet's disease-related uveitis: a multicenter retrospective observational study.
    Fabiani C; Vitale A; Emmi G; Lopalco G; Vannozzi L; Guerriero S; Gentileschi S; Bacherini D; Franceschini R; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
    Clin Rheumatol; 2017 Jan; 36(1):191-197. PubMed ID: 27981463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of sustained clinical response in patients with Behçet's disease-related uveitis treated with infliximab and adalimumab.
    Fabiani C; Vitale A; Rigante D; Emmi G; Lopalco G; Sota J; Vannozzi L; di Scala G; Guerriero S; Orlando I; Franceschini R; Capozzoli M; Frediani B; Galeazzi M; Iannone F; Tosi GM; Cantarini L
    Clin Rheumatol; 2018 Jun; 37(6):1715-1720. PubMed ID: 29671190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Infliximab therapy in Behçet's uveitis.
    Alizadegan F; Yalcinbayir O; Ucan Gunduz G; Pehlivan Y
    J Fr Ophtalmol; 2022 Nov; 45(9):1036-1041. PubMed ID: 36150991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.
    Calvo-Río V; Blanco R; Beltrán E; Sánchez-Bursón J; Mesquida M; Adán A; Hernandez MV; Hernandez Garfella M; Valls Pascual E; Martínez-Costa L; Sellas-Fernández A; Cordero Coma M; Díaz-Llopis M; Gallego R; Salom D; García Serrano JL; Ortego N; Herreras JM; Fonollosa A; García-Aparicio AM; Maíz O; Blanco A; Torre I; Fernández-Espartero C; Jovani V; Peiteado-Lopez D; Pato E; Cruz J; Fernández-Cid C; Aurrecoechea E; García M; Caracuel MA; Montilla C; Atanes A; Hernandez FF; Insua S; González-Suárez S; Sánchez-Andrade A; Gamero F; Linares L; Romero-Bueno F; García AJ; Almodovar R; Minguez E; Carrasco Cubero C; Olive A; Vázquez J; Ruiz Moreno O; Jiménez-Zorzo F; Manero J; Muñoz Fernández S; Rueda-Gotor J; González-Gay MA
    Rheumatology (Oxford); 2014 Dec; 53(12):2223-31. PubMed ID: 24996907
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of anti-tumor necrosis factor alpha agents on the outcome in pediatric uveitis of diverse etiologies.
    Deitch I; Amer R; Tomkins-Netzer O; Habot-Wilner Z; Friling R; Neumann R; Kramer M
    Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):801-808. PubMed ID: 29455252
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab for uveitis of Behçet's syndrome: a trend for earlier initiation.
    Guzelant G; Ucar D; Esatoglu SN; Hatemi G; Ozyazgan Y; Yurdakul S; Seyahi E; Yazici H; Hamuryudan V
    Clin Exp Rheumatol; 2017; 35 Suppl 108(6):86-89. PubMed ID: 29148418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: a multicenter study.
    Takeuchi M; Kezuka T; Sugita S; Keino H; Namba K; Kaburaki T; Maruyama K; Nakai K; Hijioka K; Shibuya E; Komae K; Hori J; Ohguro N; Sonoda KH; Mizuki N; Okada AA; Ishibashi T; Goto H; Mochizuki M
    Ophthalmology; 2014 Oct; 121(10):1877-84. PubMed ID: 24950593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of biologic therapy different from infliximab or adalimumab in patients with refractory uveitis due to Behçet's disease: results of a multicentre open-label study.
    Santos-Gómez M; Calvo-Río V; Blanco R; Beltrán E; Mesquida M; Adán A; Cordero-Coma M; García-Aparicio ÁM; Valls Pascual E; Martínez-Costa L; Hernández MV; Hernandez Garfella M; González-Vela MC; Pina T; Palmou-Fontana N; Loricera J; Hernández JL; González-Gay MA
    Clin Exp Rheumatol; 2016; 34(6 Suppl 102):S34-S40. PubMed ID: 27054359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the Treatment Results for Behçet Uveitis in Patients Treated with Infliximab and Interferon.
    Yalçindag N; Köse HC
    Ocul Immunol Inflamm; 2020; 28(2):305-314. PubMed ID: 31268743
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy of Infliximab for Early Remission Induction in Refractory Uveoretinitis Associated with Behçet Disease: A 2-year Follow-up Study.
    Keino H; Okada AA; Watanabe T; Nakayama M; Nakamura T
    Ocul Immunol Inflamm; 2017 Feb; 25(1):46-51. PubMed ID: 27767359
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An open-label, prospective, single-arm study of switching from infliximab to cyclosporine for refractory uveitis in patients with Behçet's disease in long-term remission.
    Ida Y; Takeuchi M; Ishihara M; Shibuya E; Yamane T; Hasumi Y; Kawano S; Kimura I; Mizuki N
    Jpn J Ophthalmol; 2021 Nov; 65(6):843-848. PubMed ID: 34586526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative efficacy between adalimumab and infliximab in the treatment of non-infectious intermediate uveitis, posterior uveitis, and panuveitis: a retrospective observational study of 107 patients.
    Fabiani C; Vitale A; Rigante D; Emmi G; Bitossi A; Lopalco G; Sota J; Guerriero S; Orlando I; Gentileschi S; Iannone F; Frediani B; Galeazzi M; Vannozzi L; Tosi GM; Cantarini L
    Clin Rheumatol; 2019 Feb; 38(2):407-415. PubMed ID: 30099655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic Treatment Options for Retinal Neovascularization in Behçet's Disease.
    Markomichelakis NN; Aissopou EK; Maselos S; Tugal-Tutkun I; Sfikakis PP
    Ocul Immunol Inflamm; 2019; 27(1):51-57. PubMed ID: 28700280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful Treatment with Infliximab for Refractory Uveitis in a Hemodialysis Patient with Behçet's Disease and a Review of the Literature for Infliximab Use in Patients on Hemodialysis.
    Kurata I; Tsuboi H; Takahashi H; Abe S; Ebe H; Hagiwara S; Umeda N; Kondo Y; Ogishima H; Suzuki T; Matsumoto I; Hoshi S; Oshika T; Sumida T
    Intern Med; 2015; 54(12):1553-7. PubMed ID: 26073249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.